What trading range was reported for the Lexeo (LXEO) COO’s share sale?

The Form 4 notes the sale was executed in multiple trades at prices between $5.06 and $5.11 per share. The disclosed weighted average sale price for the 1,302 shares was $5.074, and the insider offered to provide detailed trade breakdowns upon request.

Lexeo (LXEO) COO sells 1,302 shares in tax-related stock sale

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero reported a sale of 1,302 shares of common stock on May 18, 2026 at a weighted average price of $5.074 per share. According to the filing, this sale was made to cover tax obligations arising from the release of restricted stock units.

After the transaction, Otero holds 130,088 shares of Lexeo common stock, which includes 100,621 Restricted Stock Units. The trade was reported as a direct ownership transaction and was executed in multiple trades at prices ranging from $5.06 to $5.11 per share.

Insider Trade Summary

Net Seller: 1,302 shares ($6,606)

Net Sell 1 txn

Insider Otero Jose Manuel

Role Chief Operating Officer

Sold 1,302 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,302	$5.074	$7K

Holdings After Transaction: Common Stock — 130,088 shares (Direct, null)

Footnotes (1)

Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $5.06 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 100,621 Restricted Stock Units.

Key Figures

Shares sold: 1,302 shares Weighted average sale price: $5.074 per share Post-transaction holdings: 130,088 shares +2 more

5 metrics

Shares sold 1,302 shares Open-market sale on May 18, 2026

Weighted average sale price $5.074 per share Sale to cover RSU tax obligations

Post-transaction holdings 130,088 shares Common stock held after the sale

Restricted Stock Units included 100,621 RSUs RSUs counted within total holdings

Execution price range $5.06–$5.11 per share Multiple trades underlying weighted average price

Key Terms

Restricted Stock Units, weighted average sale price, open-market sale, tax obligations

4 terms

Restricted Stock Units financial

"Includes 100,621 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax obligations financial

"Represents a sale to cover tax obligations on the release of restricted stock units"

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last)

(First)

(Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		S⁽¹⁾		1,302	D	$5.074⁽²⁾	130,088⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $5.06 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 100,621 Restricted Stock Units.

	/s/ Youjin Choi, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Lexeo Therapeutics (LXEO) report for Jose Manuel Otero?

Lexeo Therapeutics reported that COO Jose Manuel Otero sold 1,302 shares of common stock. The sale occurred on May 18, 2026 and was disclosed as a transaction to cover tax obligations from the release of restricted stock units, rather than a discretionary portfolio trade.

How many Lexeo (LXEO) shares did the COO sell and at what price?

Jose Manuel Otero sold 1,302 Lexeo common shares at a weighted average price of $5.074. The filing notes that multiple trades were executed within a price range of $5.06 to $5.11 per share, with the reported figure representing the weighted average sale price.

Why did Lexeo COO Jose Manuel Otero sell 1,302 LXEO shares?

The sale of 1,302 Lexeo shares by COO Jose Manuel Otero was made to cover tax obligations. These taxes arose from the release of restricted stock units, meaning the transaction is characterized as tax-related rather than a purely discretionary sale in the open market.

How many Lexeo (LXEO) shares does the COO hold after this Form 4 transaction?

After the reported transaction, Jose Manuel Otero holds 130,088 Lexeo common shares. The filing specifies that this figure includes 100,621 Restricted Stock Units, giving investors a view of both his current stock position and equity-based compensation still subject to vesting conditions.